Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcomeSANZ, Miguel A; MONTESINOS, Pau; RIVAS, Concha et al.Blood. 2010, Vol 115, Num 25, pp 5137-5146, issn 0006-4971, 10 p.Article

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimensMONTESINOS, Pau; RAYON, Chelo; RIVAS, Concha et al.Blood. 2011, Vol 117, Num 6, pp 1799-1805, issn 0006-4971, 7 p.Article

Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapyBARRAGAN, Eva; MONTESINOS, Pau; COLOMER, Dolors et al.Haematologica (Roma). 2011, Vol 96, Num 10, pp 1470-1477, issn 0390-6078, 8 p.Article